NEW YORK – Danaher reported a 3 percent year-over-year increase in third quarter revenues on Tuesday even as the firm reported softness in China for its life sciences and diagnostics segments..

The Maryland-based firm said that the money will support the development and commercialization of a screening test for esophageal squamous cell carcinoma.

CEO Jim Davis said the company is on track to close eight lab acquisition deals this year, though he added that it is now in an "integration and digestion" phase.

The company reported revenues of $2.49 billion, up from $2.30 billion in the year-ago period and above the consensus Wall Street estimate of $2.42 billion.

NEW YORK – After receiving 510 (k) clearance early this month from the US Food and Drug Administration for its sepsis test, Swiss diagnostics company Abionic is targeting the US for further ...

The automated real-time PCR-based test detects DNA from the virus that causes mpox using a dual-target approach and runs on Roche's high-throughput Cobas 6800/8800 systems. The EUL process is intended ...

Last week, readers were most interested in a story about how priorities for the lab industry could play out depending on election results.

UK-based Cizzle Biotechnology signed the licensing agreement with its US-based partner, Cizzle Bio, for the commercialization of early cancer detection tests.

The EU has awarded the researchers €188,000 to support the project through September 2026, by which time they hope to have a validated prototype ready.

The Maryland-based firm reported in a recent proof-of-concept study that It used protease biomarkers to identify patients ...

The field's rapid advances make securing reimbursement an important area of focus, researchers in a recent commentary argued.